Scolaris Content Display Scolaris Content Display

Study flow diagram.
Figuras y tablas -
Figure 1

Study flow diagram.

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Figuras y tablas -
Figure 2

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
Figuras y tablas -
Figure 3

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Forest plot of comparison: 1 Any dopamine agonist versus placebo, outcome: 1.1 Dropouts.
Figuras y tablas -
Figure 4

Forest plot of comparison: 1 Any dopamine agonist versus placebo, outcome: 1.1 Dropouts.

Forest plot of comparison: 1 Any dopamine agonist versus placebo, outcome: 1.2 Adverse events as N of participants with at least one adverse event.
Figuras y tablas -
Figure 5

Forest plot of comparison: 1 Any dopamine agonist versus placebo, outcome: 1.2 Adverse events as N of participants with at least one adverse event.

Forest plot of comparison: 2 Amantadine versus placebo, outcome: 2.2 Adverse events as N of participants with at least one adverse event.
Figuras y tablas -
Figure 6

Forest plot of comparison: 2 Amantadine versus placebo, outcome: 2.2 Adverse events as N of participants with at least one adverse event.

Comparison 1 Any dopamine agonist versus placebo, Outcome 1 Dropouts.
Figuras y tablas -
Analysis 1.1

Comparison 1 Any dopamine agonist versus placebo, Outcome 1 Dropouts.

Comparison 1 Any dopamine agonist versus placebo, Outcome 2 Adverse events as N of participants with at least one adverse event.
Figuras y tablas -
Analysis 1.2

Comparison 1 Any dopamine agonist versus placebo, Outcome 2 Adverse events as N of participants with at least one adverse event.

Comparison 1 Any dopamine agonist versus placebo, Outcome 3 Dropouts due to adverse events.
Figuras y tablas -
Analysis 1.3

Comparison 1 Any dopamine agonist versus placebo, Outcome 3 Dropouts due to adverse events.

Comparison 1 Any dopamine agonist versus placebo, Outcome 4 Abstinence (objective).
Figuras y tablas -
Analysis 1.4

Comparison 1 Any dopamine agonist versus placebo, Outcome 4 Abstinence (objective).

Comparison 1 Any dopamine agonist versus placebo, Outcome 5 Abstinents at follow‐up (objective).
Figuras y tablas -
Analysis 1.5

Comparison 1 Any dopamine agonist versus placebo, Outcome 5 Abstinents at follow‐up (objective).

Comparison 1 Any dopamine agonist versus placebo, Outcome 6 Craving at the end of treatment.
Figuras y tablas -
Analysis 1.6

Comparison 1 Any dopamine agonist versus placebo, Outcome 6 Craving at the end of treatment.

Comparison 1 Any dopamine agonist versus placebo, Outcome 7 Severity of dependence (difference before and after).
Figuras y tablas -
Analysis 1.7

Comparison 1 Any dopamine agonist versus placebo, Outcome 7 Severity of dependence (difference before and after).

Comparison 1 Any dopamine agonist versus placebo, Outcome 8 Clinical global evaluation (end of treatment).
Figuras y tablas -
Analysis 1.8

Comparison 1 Any dopamine agonist versus placebo, Outcome 8 Clinical global evaluation (end of treatment).

Comparison 1 Any dopamine agonist versus placebo, Outcome 9 Depression (difference before and after ).
Figuras y tablas -
Analysis 1.9

Comparison 1 Any dopamine agonist versus placebo, Outcome 9 Depression (difference before and after ).

Comparison 2 Amantadine versus placebo, Outcome 1 Dropouts.
Figuras y tablas -
Analysis 2.1

Comparison 2 Amantadine versus placebo, Outcome 1 Dropouts.

Comparison 2 Amantadine versus placebo, Outcome 2 Adverse events as N of participants with at least one adverse event.
Figuras y tablas -
Analysis 2.2

Comparison 2 Amantadine versus placebo, Outcome 2 Adverse events as N of participants with at least one adverse event.

Comparison 2 Amantadine versus placebo, Outcome 3 Abstinence (objective).
Figuras y tablas -
Analysis 2.3

Comparison 2 Amantadine versus placebo, Outcome 3 Abstinence (objective).

Comparison 2 Amantadine versus placebo, Outcome 4 Abstinence at follow up (objective).
Figuras y tablas -
Analysis 2.4

Comparison 2 Amantadine versus placebo, Outcome 4 Abstinence at follow up (objective).

Comparison 2 Amantadine versus placebo, Outcome 5 Severity of dependence (difference before and after).
Figuras y tablas -
Analysis 2.5

Comparison 2 Amantadine versus placebo, Outcome 5 Severity of dependence (difference before and after).

Comparison 2 Amantadine versus placebo, Outcome 6 Depression (difference before and after).
Figuras y tablas -
Analysis 2.6

Comparison 2 Amantadine versus placebo, Outcome 6 Depression (difference before and after).

Comparison 3 Bromocriptine versus placebo, Outcome 1 Dropouts.
Figuras y tablas -
Analysis 3.1

Comparison 3 Bromocriptine versus placebo, Outcome 1 Dropouts.

Comparison 3 Bromocriptine versus placebo, Outcome 2 Adverse events as N of participants with at least one adverse event.
Figuras y tablas -
Analysis 3.2

Comparison 3 Bromocriptine versus placebo, Outcome 2 Adverse events as N of participants with at least one adverse event.

Comparison 4 L dopa/Carbidopa versus placebo, Outcome 1 Dropouts.
Figuras y tablas -
Analysis 4.1

Comparison 4 L dopa/Carbidopa versus placebo, Outcome 1 Dropouts.

Comparison 4 L dopa/Carbidopa versus placebo, Outcome 2 Dropouts due to adverse events.
Figuras y tablas -
Analysis 4.2

Comparison 4 L dopa/Carbidopa versus placebo, Outcome 2 Dropouts due to adverse events.

Comparison 4 L dopa/Carbidopa versus placebo, Outcome 3 Abstinence (objective).
Figuras y tablas -
Analysis 4.3

Comparison 4 L dopa/Carbidopa versus placebo, Outcome 3 Abstinence (objective).

Comparison 5 Amantidine versus antidepressants, Outcome 1 Dropouts.
Figuras y tablas -
Analysis 5.1

Comparison 5 Amantidine versus antidepressants, Outcome 1 Dropouts.

Comparison 5 Amantidine versus antidepressants, Outcome 2 Adverse events as N of participants with at least one adverse event.
Figuras y tablas -
Analysis 5.2

Comparison 5 Amantidine versus antidepressants, Outcome 2 Adverse events as N of participants with at least one adverse event.

Comparison 5 Amantidine versus antidepressants, Outcome 3 Abstinence (objective).
Figuras y tablas -
Analysis 5.3

Comparison 5 Amantidine versus antidepressants, Outcome 3 Abstinence (objective).

Summary of findings for the main comparison. Any dopamine agonist versus placebo for the treatment of cocaine dependence

Any dopamine agonist versus placebo for the treatment of cocaine dependence

Patient or population: patients with the treatment of cocaine dependence
Settings:
Intervention: Any dopamine agonist versus placebo

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of Participants
(studies)

Quality of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Control

Any dopamine agonist versus placebo

Dropouts
objective
Follow‐up: mean 6 years

Study population

RR 1.05
(0.95 to 1.15)

1643
(19 studies)

⊕⊕⊕⊝
moderate1

463 per 1000

486 per 1000
(440 to 532)

Medium risk population

482 per 1000

506 per 1000
(458 to 554)

Adverse events as N of participants with at least one adverse event
subjective and objective
Follow‐up: mean 6 weeks

Study population

RR 1.29
(0.88 to 1.91)

210
(6 studies)

⊕⊕⊕⊝
moderate1

308 per 1000

397 per 1000
(271 to 588)

Medium risk population

300 per 1000

387 per 1000
(264 to 573)

Abstinence (objective)
objective
Follow‐up: mean 6 weeks

Study population

RR 1.09
(0.93 to 1.28)

761
(11 studies)

⊕⊕⊝⊝
low1,2

360 per 1000

392 per 1000
(335 to 461)

Medium risk population

500 per 1000

545 per 1000
(465 to 640)

Abstinents at follow‐up (objective)
objective
Follow‐up: mean 6 weeks

Study population

OR 0.81
(0.41 to 1.57)

166
(4 studies)

⊕⊕⊝⊝
low1,2

733 per 1000

690 per 1000
(530 to 812)

Medium risk population

744 per 1000

702 per 1000
(544 to 820)

Severity of dependence (difference before and after)
ASI
Follow‐up: mean 6 weeks

The mean Severity of dependence (difference before and after) in the intervention groups was
0.43 standard deviations higher
(0.15 to 0.71 higher)

232
(4 studies)

⊕⊕⊕⊝
moderate1

SMD 0.43 (0.15 to 0.71)

Depression (difference before and after )
Beck Depression Inventory
Follow‐up: mean 6 weeks

The mean Depression (difference before and after ) in the intervention groups was
0.42 standard deviations higher
(0.19 to 0.65 higher)

322
(5 studies)

⊕⊕⊕⊝
moderate1

SMD 0.42 (0.19 to 0.65)

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1 The majority of studies were classified as at unclear risk of bias for sequence generation and method of allocation concealment;
2 Overlap of confidence interval

Figuras y tablas -
Summary of findings for the main comparison. Any dopamine agonist versus placebo for the treatment of cocaine dependence
Summary of findings 2. Amantadine versus placebo for the treatment of cocaine dependence

Amantadine versus placebo for the treatment of cocaine dependence

Patient or population: patients with the treatment of cocaine dependence
Settings:
Intervention: Amantadine versus placebo

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of Participants
(studies)

Quality of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Control

Amantadine versus placebo

Dropouts
objective
Follow‐up: mean 6 weeks

Study population

RR 0.98
(0.77 to 1.26)

484
(9 studies)

⊕⊕⊕⊝
moderate1

378 per 1000

370 per 1000
(291 to 476)

Medium risk population

286 per 1000

280 per 1000
(220 to 360)

Adverse events as N of participants with at least one adverse event
objective
Follow‐up: mean 6 weeks

Study population

RR 1.09
(0.69 to 1.74)

128
(4 studies)

⊕⊕⊕⊕
high

329 per 1000

359 per 1000
(227 to 572)

Medium risk population

300 per 1000

327 per 1000
(207 to 522)

Abstinence (objective)
objective
Follow‐up: mean 6 weeks

Study population

RR 1.08
(0.77 to 1.51)

275
(5 studies)

⊕⊕⊕⊝
moderate1

307 per 1000

332 per 1000
(236 to 464)

Medium risk population

355 per 1000

383 per 1000
(273 to 536)

Abstinence at follow up (objective)
objective
Follow‐up: mean 6 weeks

Study population

RR 1.43
(0.99 to 2.08)

76
(3 studies)

⊕⊕⊕⊝
moderate1

512 per 1000

732 per 1000
(507 to 1000)

Medium risk population

526 per 1000

752 per 1000
(521 to 1000)

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1 The majority of studies were classified as at unclear risk of bias for sequence generation and method of allocation concealment;

Figuras y tablas -
Summary of findings 2. Amantadine versus placebo for the treatment of cocaine dependence
Summary of findings 3. Amantidine versus antidepressants for the treatment of cocaine dependence

Amantidine versus antidepressants for the treatment of cocaine dependence

Patient or population: patients with the treatment of cocaine dependence
Settings:
Intervention: Amantidine versus antidepressants

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of Participants
(studies)

Quality of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Control

Amantidine versus antidepressants

Dropouts
objective
Follow‐up: mean 6 weeks

Study population

RR 0.9
(0.57 to 1.44)

153
(4 studies)

⊕⊕⊕⊝
moderate1

329 per 1000

296 per 1000
(188 to 474)

Medium risk population

267 per 1000

240 per 1000
(152 to 384)

Adverse events as N of participants with at least one adverse event
objective
Follow‐up: mean 6 weeks

Study population

RR 0.54
(0.17 to 1.7)

44
(2 studies)

⊕⊕⊕⊕
high

320 per 1000

173 per 1000
(54 to 544)

Medium risk population

335 per 1000

181 per 1000
(57 to 570)

Abstinence (objective)
objective
Follow‐up: mean 6 weeks

Study population

RR 0.25
(0.12 to 0.53)

68
(2 studies)

⊕⊕⊕⊕
high

775 per 1000

194 per 1000
(93 to 411)

Medium risk population

859 per 1000

215 per 1000
(103 to 455)

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1 The majority of studies were classified as at unclear risk of bias for sequence generation and method of allocation concealment;

Figuras y tablas -
Summary of findings 3. Amantidine versus antidepressants for the treatment of cocaine dependence
Table 1. Assessment of risk of bias in the included studies

 Item

 Judgment

 Description

1. random sequence generation (selection bias)

 

 

Low risk

The investigators describe a random component in the sequence generation process such as: random number table; computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots; minimization

High risk

The investigators describe a non‐random component in the sequence generation process such as: odd or even date of birth; date (or day) of admission; hospital or clinic record number; alternation; judgement of the clinician; results of a laboratory test or a series of tests; availability of the intervention

Unclear risk

Insufficient information about the sequence generation process to permit judgement of low or high risk

2. allocation concealment (selection bias)

 

 

Low risk

Investigators enrolling participants could not foresee assignment because one of the following, or an equivalent method, was used to conceal allocation: central allocation (including telephone, web‐based, and pharmacy‐controlled, randomisation); sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes.

High risk

Investigators enrolling participants could possibly foresee assignments because one of the following method was used: open random allocation schedule (e.g. a list of random numbers); assignment envelopes without appropriate safeguards (e.g. if envelopes were unsealed or non­opaque or not sequentially numbered); alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure.

Unclear risk

Insufficient information to permit judgement of low or high risk This is usually the case if the method of concealment is not described or not described in sufficient detail to allow a definite judgement

3. blinding of participants and providers (performance bias)

subjective outcomes

 

 

Low risk

 

 

No blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding;

Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.

 

High risk

No blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding;

Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding.

Unclear risk

Insufficient information to permit judgement of low or high risk;

4. blinding of outcome assessor (detection bias)

Subjective outcomes 

 

 

Low risk

 

 

No blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding;

Blinding of outcome assessment ensured, and unlikely that the blinding could have been broken

High risk

No blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding;

Blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding

Unclear risk

Insufficient information to permit judgement of low or high risk;

5. incomplete outcome data (attrition bias)

For all outcomes except retention in treatment or drop out

 

 

Low risk

 

 

 

No missing outcome data;

Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias);

Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups;

For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate;

For continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size;

Missing data have been imputed using appropriate methods

All randomised patients are reported/analysed in the group they were allocated to by randomisation irrespective of non‐compliance and co‐interventions (intention to treat)

High risk

Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups;

For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate;

For continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size;

‘As‐treated’ analysis done with substantial departure of the intervention received from that assigned at randomisation; 

Unclear risk

Insufficient information to permit judgement of low or high risk (e.g. number randomised not stated, no reasons for missing data provided; number of drop out not reported for each group);

6 selective reporting (reporting bias)

 

 

Low risk

The study protocol is available and all of the study’s pre‐specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre‐specified way;

The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre‐specified (convincing text of this nature may be uncommon).

High risk

Not all of the study’s pre‐specified primary outcomes have been reported;

One or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre‐specified;

One or more reported primary outcomes were not pre‐specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect);

One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta‐analysis;

The study report fails to include results for a key outcome that would be expected to have been reported for such a study.

Unclear risk

Insufficient information to permit judgement of low or high risk

Figuras y tablas -
Table 1. Assessment of risk of bias in the included studies
Comparison 1. Any dopamine agonist versus placebo

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Dropouts Show forest plot

19

1643

Risk Ratio (M‐H, Fixed, 95% CI)

1.05 [0.95, 1.15]

2 Adverse events as N of participants with at least one adverse event Show forest plot

6

210

Risk Ratio (M‐H, Fixed, 95% CI)

1.29 [0.88, 1.91]

3 Dropouts due to adverse events Show forest plot

3

325

Risk Ratio (M‐H, Fixed, 95% CI)

1.08 [0.16, 7.47]

4 Abstinence (objective) Show forest plot

11

761

Risk Ratio (M‐H, Fixed, 95% CI)

1.09 [0.93, 1.28]

5 Abstinents at follow‐up (objective) Show forest plot

4

166

Risk Ratio (M‐H, Fixed, 95% CI)

0.94 [0.77, 1.14]

6 Craving at the end of treatment Show forest plot

3

151

Std. Mean Difference (IV, Fixed, 95% CI)

0.13 [‐0.19, 0.45]

7 Severity of dependence (difference before and after) Show forest plot

4

232

Std. Mean Difference (IV, Fixed, 95% CI)

0.43 [0.15, 0.71]

8 Clinical global evaluation (end of treatment) Show forest plot

2

130

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.12 [‐0.47, 0.22]

9 Depression (difference before and after ) Show forest plot

5

322

Std. Mean Difference (IV, Fixed, 95% CI)

0.42 [0.19, 0.65]

Figuras y tablas -
Comparison 1. Any dopamine agonist versus placebo
Comparison 2. Amantadine versus placebo

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Dropouts Show forest plot

9

484

Risk Ratio (M‐H, Random, 95% CI)

0.98 [0.77, 1.26]

2 Adverse events as N of participants with at least one adverse event Show forest plot

4

128

Risk Ratio (M‐H, Fixed, 95% CI)

1.09 [0.69, 1.74]

3 Abstinence (objective) Show forest plot

5

275

Risk Ratio (M‐H, Fixed, 95% CI)

1.08 [0.77, 1.51]

4 Abstinence at follow up (objective) Show forest plot

3

76

Risk Ratio (M‐H, Fixed, 95% CI)

1.43 [0.99, 2.08]

5 Severity of dependence (difference before and after) Show forest plot

2

102

Std. Mean Difference (IV, Fixed, 95% CI)

0.39 [‐0.00, 0.79]

6 Depression (difference before and after) Show forest plot

2

109

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.37 [‐0.76, 0.02]

Figuras y tablas -
Comparison 2. Amantadine versus placebo
Comparison 3. Bromocriptine versus placebo

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Dropouts Show forest plot

5

242

Risk Ratio (M‐H, Fixed, 95% CI)

1.03 [0.74, 1.44]

2 Adverse events as N of participants with at least one adverse event Show forest plot

2

89

Risk Ratio (M‐H, Random, 95% CI)

0.92 [0.38, 2.22]

Figuras y tablas -
Comparison 3. Bromocriptine versus placebo
Comparison 4. L dopa/Carbidopa versus placebo

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Dropouts Show forest plot

3

219

Risk Ratio (M‐H, Fixed, 95% CI)

0.91 [0.74, 1.13]

2 Dropouts due to adverse events Show forest plot

3

325

Risk Ratio (M‐H, Fixed, 95% CI)

1.08 [0.16, 7.47]

3 Abstinence (objective) Show forest plot

4

355

Odds Ratio (M‐H, Fixed, 95% CI)

1.49 [0.85, 2.63]

Figuras y tablas -
Comparison 4. L dopa/Carbidopa versus placebo
Comparison 5. Amantidine versus antidepressants

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Dropouts Show forest plot

4

153

Risk Ratio (M‐H, Fixed, 95% CI)

0.90 [0.57, 1.44]

2 Adverse events as N of participants with at least one adverse event Show forest plot

2

44

Risk Ratio (M‐H, Fixed, 95% CI)

0.54 [0.17, 1.70]

3 Abstinence (objective) Show forest plot

2

68

Risk Ratio (M‐H, Fixed, 95% CI)

0.25 [0.12, 0.53]

Figuras y tablas -
Comparison 5. Amantidine versus antidepressants